AKRO
Price
$54.28
Change
+$0.34 (+0.63%)
Updated
Jun 6 closing price
Capitalization
4.31B
62 days until earnings call
MDWD
Price
$21.60
Change
-$0.07 (-0.32%)
Updated
Jun 6 closing price
Capitalization
233.45M
66 days until earnings call
Interact to see
Advertisement

AKRO vs MDWD

Header iconAKRO vs MDWD Comparison
Open Charts AKRO vs MDWDBanner chart's image
Akero Therapeutics
Price$54.28
Change+$0.34 (+0.63%)
Volume$1.47M
Capitalization4.31B
MediWound
Price$21.60
Change-$0.07 (-0.32%)
Volume$40.15K
Capitalization233.45M
AKRO vs MDWD Comparison Chart
Loading...
AKRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDWD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AKRO vs. MDWD commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKRO is a Buy and MDWD is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (AKRO: $54.28 vs. MDWD: $21.60)
Brand notoriety: AKRO and MDWD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKRO: 88% vs. MDWD: 56%
Market capitalization -- AKRO: $4.31B vs. MDWD: $233.45M
AKRO [@Biotechnology] is valued at $4.31B. MDWD’s [@Biotechnology] market capitalization is $233.45M. The market cap for tickers in the [@Biotechnology] industry ranges from $324.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKRO’s FA Score shows that 0 FA rating(s) are green whileMDWD’s FA Score has 1 green FA rating(s).

  • AKRO’s FA Score: 0 green, 5 red.
  • MDWD’s FA Score: 1 green, 4 red.
According to our system of comparison, AKRO is a better buy in the long-term than MDWD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKRO’s TA Score shows that 6 TA indicator(s) are bullish while MDWD’s TA Score has 4 bullish TA indicator(s).

  • AKRO’s TA Score: 6 bullish, 4 bearish.
  • MDWD’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, AKRO is a better buy in the short-term than MDWD.

Price Growth

AKRO (@Biotechnology) experienced а +9.33% price change this week, while MDWD (@Biotechnology) price change was -1.64% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.04%. For the same industry, the average monthly price growth was +14.90%, and the average quarterly price growth was +1.90%.

Reported Earning Dates

AKRO is expected to report earnings on Aug 08, 2025.

MDWD is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+9.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AKRO($4.31B) has a higher market cap than MDWD($233M). AKRO YTD gains are higher at: 95.111 vs. MDWD (21.348). MDWD has higher annual earnings (EBITDA): -6.58M vs. AKRO (-247.37M). AKRO has more cash in the bank: 743M vs. MDWD (45.6M). MDWD has less debt than AKRO: MDWD (6.46M) vs AKRO (36.5M). MDWD has higher revenues than AKRO: MDWD (19.7M) vs AKRO (0).
AKROMDWDAKRO / MDWD
Capitalization4.31B233M1,848%
EBITDA-247.37M-6.58M3,762%
Gain YTD95.11121.348446%
P/E RatioN/AN/A-
Revenue019.7M-
Total Cash743M45.6M1,629%
Total Debt36.5M6.46M565%
FUNDAMENTALS RATINGS
AKRO vs MDWD: Fundamental Ratings
AKRO
MDWD
OUTLOOK RATING
1..100
2525
VALUATION
overvalued / fair valued / undervalued
1..100
45
Fair valued
68
Overvalued
PROFIT vs RISK RATING
1..100
5278
SMR RATING
1..100
9195
PRICE GROWTH RATING
1..100
3639
P/E GROWTH RATING
1..100
1003
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AKRO's Valuation (45) in the null industry is in the same range as MDWD (68) in the Pharmaceuticals Other industry. This means that AKRO’s stock grew similarly to MDWD’s over the last 12 months.

AKRO's Profit vs Risk Rating (52) in the null industry is in the same range as MDWD (78) in the Pharmaceuticals Other industry. This means that AKRO’s stock grew similarly to MDWD’s over the last 12 months.

AKRO's SMR Rating (91) in the null industry is in the same range as MDWD (95) in the Pharmaceuticals Other industry. This means that AKRO’s stock grew similarly to MDWD’s over the last 12 months.

AKRO's Price Growth Rating (36) in the null industry is in the same range as MDWD (39) in the Pharmaceuticals Other industry. This means that AKRO’s stock grew similarly to MDWD’s over the last 12 months.

MDWD's P/E Growth Rating (3) in the Pharmaceuticals Other industry is significantly better than the same rating for AKRO (100) in the null industry. This means that MDWD’s stock grew significantly faster than AKRO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AKROMDWD
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
86%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
88%
Momentum
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
78%
MACD
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
77%
Advances
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 5 days ago
77%
Declines
ODDS (%)
Bearish Trend 10 days ago
84%
Bearish Trend 1 day ago
82%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
89%
Aroon
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
AKRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDWD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
QDEF72.820.51
+0.71%
FlexShares Quality Dividend Defensv ETF
KTEC16.150.03
+0.19%
KraneShares Hang Seng TECH ETF
TINT29.26N/A
N/A
ProShares Smart Materials ETF
IBTH22.30-0.06
-0.27%
iShares iBonds Dec 2027 Term Tr ETF
MPA10.77-0.06
-0.55%
Blackrock Muniyield Pennsylvania Quality Fund

AKRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKRO has been loosely correlated with ETNB. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if AKRO jumps, then ETNB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKRO
1D Price
Change %
AKRO100%
+0.63%
ETNB - AKRO
60%
Loosely correlated
+2.91%
SLS - AKRO
41%
Loosely correlated
-1.23%
TRDA - AKRO
40%
Loosely correlated
+2.46%
IDYA - AKRO
39%
Loosely correlated
+2.99%
VTYX - AKRO
38%
Loosely correlated
+9.33%
More

MDWD and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDWD has been loosely correlated with PHIO. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if MDWD jumps, then PHIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDWD
1D Price
Change %
MDWD100%
-0.32%
PHIO - MDWD
35%
Loosely correlated
+20.33%
AKRO - MDWD
33%
Poorly correlated
+0.63%
INSM - MDWD
32%
Poorly correlated
+1.21%
KANT - MDWD
30%
Poorly correlated
+8.49%
VCEL - MDWD
27%
Poorly correlated
-0.23%
More